# A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab

> **NCT06681298** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **xiaohua li** · enrollment: 36 (estimated)

## Conditions studied

- Adenocarcinoma of the Esophagogastric Junction
- Perioperative Period

## Interventions

- **DRUG:** The experimental group received Nivolumab

## Key facts

- **NCT ID:** NCT06681298
- **Lead sponsor:** xiaohua li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2029-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06681298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06681298, "A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06681298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*